← Back to Search

BMS-986308 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 72 days

Summary

This trial is testing a new drug called BMS-986308 to see if it is safe and how it affects healthy people. Researchers want to know how the drug behaves in the body and if it causes any side effects.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 72 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 72 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests
Incidence of clinically significant changes in clinical laboratory results: Hematology tests
Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests
Other study objectives
Incidence of Adverse Events (AEs)
Incidence of adverse events (AEs) leading to discontinuation
Incidence of clinically significant changes in cardiac telemetry
+11 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Part B (SAD)Experimental Treatment2 Interventions
Single Ascending Dose (SAD)
Group II: Part A FurosemideExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-986308
2021
Completed Phase 1
~50
Furosemide
2015
Completed Phase 4
~4240

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,688 Previous Clinical Trials
4,096,761 Total Patients Enrolled
~10 spots leftby Dec 2025